Business Context and Reporting Period
This Form 8-K, dated June 7, 2019, reports the completion of a business combination between Stellar Biotechnologies, Inc. ("Stellar") and Edesa Biotech Inc. ("Edesa"). Stellar acquired all issued share capital of Edesa, making Edesa a wholly-owned subsidiary. Concurrently, the Company changed its name from Stellar Biotechnologies, Inc. to Edesa Biotech, Inc. and effected a 1-for-6 reverse split of its common shares. The combined entity is a biopharmaceutical company focused on developing therapeutics for dermatological and gastrointestinal indications.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or margin figures for the reporting period, as these financial statements are scheduled to be filed in an amendment by August 23, 2019. However, the following capital structure metrics are disclosed:
- Shares Issued to Edesa Shareholders: Approximately 6,249,780 Stellar Common Shares.
- Replacement Options: Approximately 321,885 options to purchase Stellar Common Shares issued to former Edesa option holders.
- Post-Closing Outstanding Shares: Approximately 7,138,233 Stellar Common Shares issued and outstanding immediately following the Closing and Reverse Split.
- Fully Diluted Shares: Approximately 7,467,801 Stellar Common Shares.
- Ownership Split: Former Edesa shareholders and option holders own approximately 88% of the fully diluted shares; former Stellar shareholders and option holders own approximately 12%.
- Working Capital Adjustment: The 88/12 split resulted because Stellar's estimated working capital exceeded $3.5 million prior to the Exchange.
Material Changes Versus Prior Period
The primary material change is the change in control and corporate identity. Stellar Biotechnologies, Inc. no longer exists as the primary operating entity; the business is now conducted under the name Edesa Biotech, Inc. The ticker symbol changed from "SBOT" to "EDSA" on The Nasdaq Capital Market effective June 10, 2019. The Company also changed its independent registered public accounting firm from Moss Adams LLP to MNP LLP.
Guidance, Outlook, and Management Commentary
The filing does not contain forward-looking financial guidance or specific outlook metrics. Management commentary focuses on the strategic rationale of the combination, noting that the primary business is now Edesa's development of innovative therapeutics. The Company expects to file audited financial statements for Edesa and unaudited pro forma combined financial statements in an amendment to this report by August 23, 2019.
Risks and Contingencies: The number of shares issued to Edesa shareholders is subject to adjustment within 35 days of the Closing to account for warrant holder cash payout requests. Additionally, the Company is finalizing employment agreements for the new CEO and President, which will be disclosed in a subsequent amendment.
Important Facts for Investor Verification
- Verify the final share count and ownership percentages once the 35-day adjustment period for warrant cash-outs concludes.
- Review the upcoming August 23, 2019 amendment for Edesa's audited financial statements and pro forma combined financial data to assess the combined entity's liquidity and debt position.
- Confirm the terms of the employment agreements for Dr. Pardeep Nijhawan (CEO) and Michael Brooks (President), which are pending finalization.
- Note the change in auditor to MNP LLP and review the transition details in the filed exhibits.
- Monitor the trading of the new ticker symbol "EDSA" on The Nasdaq Capital Market post-reverse split.